Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] is supplied in single-dose amber vials. Each single-dose vial of sterile aqueous solution contains 10 mg per mL of hydromorphone hydrochloride with 0.2% sodium citrate and 0.2% citric acid solution. Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] is preservative free and is supplied as follows:
| Unit of Sale | Concentration |
|---|---|
| |
NDC 0409-2634-01 | 10 mg/mL |
NDC 0409-2634-05 | 50 mg/5 mL (10 mg/mL) |
NDC 0409-2634-50 | 500 mg/50 mL (10 mg/mL) |
No added preservative.
PROTECT FROM LIGHT.
Keep covered in carton until time of use. Store at 20° to 25°C (68° to 77°F); [see USP Controlled Room Temperature].
Safety and Handling Instructions
Access to drugs with a potential for abuse such as Hydromorphone Hydrochloride Injection, USP [high potency formulation (HPF)] presents an occupational hazard for addiction in the healthcare industry. Routine procedures for handling controlled substances developed to protect the public may not be adequate to protect healthcare workers. Implementation of more effective accounting procedures and measures to restrict access to drugs of this class (appropriate to the practice setting) may minimize the risk of self-administration by healthcare providers.
Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] is supplied in single-dose amber vials. Each single-dose vial of sterile aqueous solution contains 10 mg per mL of hydromorphone hydrochloride with 0.2% sodium citrate and 0.2% citric acid solution. Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] is preservative free and is supplied as follows:
| Unit of Sale | Concentration |
|---|---|
| |
NDC 0409-2634-01 | 10 mg/mL |
NDC 0409-2634-05 | 50 mg/5 mL (10 mg/mL) |
NDC 0409-2634-50 | 500 mg/50 mL (10 mg/mL) |
No added preservative.
PROTECT FROM LIGHT.
Keep covered in carton until time of use. Store at 20° to 25°C (68° to 77°F); [see USP Controlled Room Temperature].
Safety and Handling Instructions
Access to drugs with a potential for abuse such as Hydromorphone Hydrochloride Injection, USP [high potency formulation (HPF)] presents an occupational hazard for addiction in the healthcare industry. Routine procedures for handling controlled substances developed to protect the public may not be adequate to protect healthcare workers. Implementation of more effective accounting procedures and measures to restrict access to drugs of this class (appropriate to the practice setting) may minimize the risk of self-administration by healthcare providers.
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.